secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2022-11-28T23:59:59+00:00
Accession:  0001104659-22-122454
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 1.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BMS terminates collaboration with uniQure effective Feb 21, 2023
----------------------------------------------------------------

- Bristol-Myers Squibb provided termination notice for collaboration and license agreement originally dated May 2015.
- Termination is effective February 21, 2023; the agreement was amended in December 2020.
- BMS did not replace any of the four active Collaboration Targets during the one-year option period.
- A change-of-control payment of up to $70M to BMS is still contingent; no such transaction has occurred.
- The separate Investor Agreement between uniQure and BMS remains in force per its terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000110465922122454/0001104659-22-122454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000110465922122454/tm2231450d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-122454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer